Focused On-demand Library for Interleukin-1 receptor accessory protein-like 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9NZN1

UPID:

IRPL1_HUMAN

Alternative names:

Oligophrenin-4; Three immunoglobulin domain-containing IL-1 receptor-related 2; X-linked interleukin-1 receptor accessory protein-like 1

Alternative UPACC:

Q9NZN1; A0AVG4; Q9UJ53

Background:

Interleukin-1 receptor accessory protein-like 1, also known as Oligophrenin-4, plays a pivotal role in neuronal development. It regulates secretion, presynaptic differentiation, and neurite outgrowth. This protein's ability to modulate N-type voltage-gated calcium channel activity and activate the MAP kinase JNK underscores its significance in neurobiological processes.

Therapeutic significance:

Linked to Intellectual developmental disorder, X-linked 21, Interleukin-1 receptor accessory protein-like 1's dysfunction highlights its potential as a therapeutic target. Understanding its role could open doors to novel strategies for treating intellectual disabilities.